Apollomics Reveals Resolution of Legal Dispute in Cayman Islands

Settlement Agreement: Apollomics Inc. has reached a settlement with TWVC Goldlink Partners and TWVC Panglin Group regarding a lawsuit in the Cayman Islands, resolving disputes over preferred share redemptions prior to a merger with Maxpro Capital Acquisition Corporation.

Financial Terms: The settlement includes a payment of $5 million in cash, to be made in installments over two years, along with approximately $879,757.78 for legal expenses, while TWVC will withdraw all claims against Apollomics.

Litigation Background: The original claims by TWVC amounted to around $40 million, as noted in Apollomics' Form 20-F filed in April 2025, and the settlement is pending court approval to conclude the litigation.

Company Overview: Apollomics is a clinical-stage biopharmaceutical company focused on developing oncology therapies, with its lead program being vebreltinib, a selective c-Met inhibitor currently in Phase 2 clinical trials.